Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review

Chenchula, Santenna; Amerneni, Krishna Chaitanya; Ghanta, Mohan Krishna; Padmavathi, R; Chandra, Madhu Bhargavi; Adusumilli, Madhu Babu; Chavan, Madhavrao; Mudda, Sofia; Gupta, Rupesh; Lakhawat, Bhawna

doi:10.1016/j.virol.2023.04.007

Cited by 13 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pfizer-BioNTech) should undergo vaccination with any one of the approved vaccines." 220,221 Therefore, along with preventive measures with COVID-19 vaccination, regular physical activity in individuals with obesity has been shown to cut the mortality rate due to influenza and pneumonia. 222 In addition, a healthy diet with prior caloric and nutritional counting of every bowl also benefits subjects with obesity.…”

Section: Publication Biasmentioning

confidence: 99%

Prevalence of overweight and obesity and their effect on COVID‐19 severity and hospitalization among younger than 50 years versus older than 50 years population: A systematic review and meta‐analysis

et al. 2023

Self Cite

View full text Add to dashboard Cite

SummaryCohort studies have shown that both overweight and obesity have their impact by increasing hospitalization with COVID‐19. We conducted a systematic literature search in PubMed, Google Scholar, and MedRxiv databases following the PRISMA guidelines. Statistical analyses were performed using STATA software version 16 MP (Stata Corp, College Station, TX, USA) and Med Calc software version 22.009(Med Calc software Ltd, Ostend, Belgium). The primary outcome was to measure the prevalence of overweight and obesity and their impact on the risk of hospitalization among COVID‐19 patients under and above 50 years of age. In total, 184 studies involving 2,365,377 patients were included. The prevalence of overweight was highest among those younger than 50 years of age over those older than 50 years of age, (26.33% vs. 30.46%), but there was no difference in obesity (36.30% vs. 36.02%). Overall, the pooled prevalence of overweight and obesity among hospitalized COVID‐19 patients was 31.0% and 36.26%, respectively. Compared with normal weight, the odds of hospitalization with overweight (odds ratio [OR] 2.186, 95% confidence interval [CI] [1.19, 3.99], p < 0.01) and obesity (OR 3.069, 95% CI [1.67, 5.61], p < 0.001) in those younger than 50 years and obesity (OR 3.977, 95% CI [2.75, 5.73], p < 0.001) in the older than 50 years age group were significantly high. The increased prevalence of overweight and obesity among the under 50 years age group and obesity among the older than 50 years age group significantly increased the rate of COVID‐19 infections, severity and hospitalization.

show abstract

Section: Publication Biasmentioning

confidence: 99%

Prevalence of overweight and obesity and their effect on COVID‐19 severity and hospitalization among younger than 50 years versus older than 50 years population: A systematic review and meta‐analysis

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…COVID-19 boosters in these individuals aim to reduce their occupational risk of infection and transmission to vulnerable populations. Bivalent boosters may provide protection against hospitalisation and severe symptoms caused by various SARS-CoV-2 variants [ 7 , 8 , 26 , 27 , 28 ], particularly in individuals with “hybrid immunity” [ 1 , 2 , 3 , 4 , 5 , 7 , 8 ]. Such boosters can enhance both humoral and cellular immunity, decrease infection rates, and offer protection, especially for specific populations such as organ transplant recipients, dialysis patients, individuals with chronic renal disease, the elderly population, and immunocompromised individuals [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

Pitak-Arnnop,

Ngamskulrungroj,

Mahanonda

et al. 2024

Medicina

View full text Add to dashboard Cite

While the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research to offer health care providers (HCPs) a comprehensive guide on COVID-19 boosters in 2024. The review outlines key recommendations from the German Robert Koch Institute. HCPs should receive COVID-19 boosters at least 12 months after their last vaccination or COVID-19 infection, contingent on the prevalent viral variant(s) in the region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead to immune imprinting, T-cell exhaustion, and immunoglobulin (Ig) switching. Notably, this review highlights the significance of Ig, particularly IgA and IgG subclasses, in influencing infection risk and disease progression. Furthermore, it explores the implications of mRNA vaccine technology and potential adverse effects related to excessive dosing. In conclusion, this article provides a comprehensive analysis of COVID-19 vaccine boosters for HCPs, synthesising current recommendations, scientific debates, and considerations for optimising protection against SARS-CoV-2 in the evolving landscape of the post-pandemic era.

show abstract

“…In the current era of antimicrobial resistance across the world, irrational use of antibiotics for the treatment of antivirals, fuels the emergence of multidrug resistant bacteria [ 39 , 40 , 41 , 43 ]. Currently highly infectious omicron variants and novel viral infections like Mpox, stake holders and policy makers must take significant action regarding irrational use of antimicrobial agents across the world [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiology, clinical presentation and treatment outcomes in patients with COVID-19 in an ambulatory setting: a cross sectional study during the massive SARS-CoV-2 wave in India

Sharma

2023

Bioinformation

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by SARS-CoV-2, has profoundly affected developing countries like India. This retrospective cross-sectional analysis investigated epidemiological, clinical characteristics, treatment strategies, and outcomes for hospitalized COVID-19 patients during the Massive SARS-CoV-2 Wave in India. Among 233 patients, the median age was 47.33 years, mostly male. Hospital stays averaged 8.4 days. Common symptoms include fever (88.41%), dry cough (56.2%), myalgia (44.20%), and shortness of breath (22.8%). The most common comorbidities were diabetes mellitus (52%) and hypertension (47.2%). Elevated biomarkers include D-dimer (24.4%), CRP (32.1%), ferritin (26.60%), and others. Prescription analysis revealed that antibiotics (42.6%), Antivirals (37%), anthelmintics (20.30%), vitamins and nutritional supplements (20.71%) and glucocorticoids (12.8%) were the most commonly prescribed. Oxygen therapy was needed by 19.31% of patients in the moderate and severe categories within 24 hours of admission. The mortality rate was 8.58%. The surge led to increased hospitalizations and mortality, particularly among young adults. Diabetes and hypertension were correlated with mortality. Irregular use of drugs lacking evidence, like antibiotics and anthelmintics, vitamins and nutritional supplements, was observed in COVID-19 management. This study underscores the impact of the pandemic in India and highlights the need for evidence-based treatments.

show abstract

Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review

Cited by 13 publications

References 19 publications

Prevalence of overweight and obesity and their effect on COVID‐19 severity and hospitalization among younger than 50 years versus older than 50 years population: A systematic review and meta‐analysis

Prevalence of overweight and obesity and their effect on COVID‐19 severity and hospitalization among younger than 50 years versus older than 50 years population: A systematic review and meta‐analysis

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

Epidemiology, clinical presentation and treatment outcomes in patients with COVID-19 in an ambulatory setting: a cross sectional study during the massive SARS-CoV-2 wave in India

Contact Info

Product

Resources

About